2025.Mar.28

Corporate

GlycOBI® Advances Bispecific and Dual Payload ADC Development
OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston

The highly anticipated 4th Novel Conjugates Summit, drawing global industry attention, took place in Boston, USA, from 3/25 to 3/27. OBI Pharma (4174.TWO) showcased its innovative Antibody-Drug Conjugate (ADC) technology platform, GlycOBI®, and emphasized its unique strengths and versability in the development of bispecific (BsADCs) and dual payload ADCs.

HOMEWhat’s NewNewsGlycOBI® Advances Bispecific and Dual Payload ADC Development OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Mar.26

OBI Wins " Most Promising Immunotherapy Pipeline" Award Showcasing TROP2 ADC Research at Biologics World Taiwan

2025.Apr.23

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.